| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.088 | 0.09 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.09 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.09 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.065 | 0.09 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.091 | 0.1 |